This site is intended for health professionals only
Swiss drug maker Roche have announced that its drug, MabThera is continuing to improve patient response in rheumatoid arthritis with multiple courses of treatment and they also said that it was well tolerated over the long term.
In a study carried out with the drug, patients had not responded adequately to another class of rheumatoid arthritis drug commonly prescribed as the first-line biologic therapy – known as tumour necrosis factor (TNF) inhibitors.
Professor Edward Keystone, Rheumatology Department at the University of Toronto, Canada, commented on the drug: “Prolonged treatment with MabThera clearly demonstrates an improvement in symptoms for patients with rheumatoid arthritis who do not respond adequately to TNF inhibitor therapy.”
Roche will be presenting the data at the American College of Rheumatology’s annual meeting in San Francisco.